News Room
Technophage announces FDA Fast Track Designation Granted to TP-102 for the treatment of patients with infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii
Technophage announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TP-102, the company’s first...
Interview to Link to Leaders by Miguel Garcia, CEO of Technophage
In the past few months, and due to the recently initiated Phase I/IIa Clinical Trial of the bacteriophage cocktail TP-102, which has been entirely...
The radiopharmaceutical way to diagnose Alzheimer’s Disease
In a joint effort to tackle Alzheimer's Disease (AD), Technophage in collaboration with ICNAS (Instituto de Ciências Nucleares Aplicadas à Saúde) is...
Pipeline
Invest in our products
GMP manufacturing
Learn more about GMP manufacturing
Technophage
Who we are, What we do
Therapeutic
areas
TechnoPhage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology